IL2 and neoplasm: While cytokine administration, namely IL-2, has historically been shown to have anti-tumor activity on their own (43), they are becoming increasingly used within the context of cellular immunotherapy, either via systemic administration or encoded within the cellular product to enhance therapeutic efficacy.